Author

J. F. Shern

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. J. Thiele· 2 shared H. Lei· 2 shared M. Xu· 2 shared X. Zhang· 2 shared Z. Liu· 2 shared A. Ciardiello· 1 shared C. A. Keller· 1 shared C. A. Ricker· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. J. Thiele

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes

Z. Liu, X. Zhang, M. Xu, J. J. Hong, A. Ciardiello, H. Lei, J. F. Shern, C. J. Thiele

This study shows MYCN drives oncogenesis by cooperating with WDR5 to activate MYC targets and G9a to repress differentiation genes, and targeting both synergistically inhibits neuroblastoma growth.

bioRxiv · Jul 11, 2023 · PreprintCancer Biology

A "cooperative collaboration" between HAND2 and MYCN shapes neuroblastoma cell identity

M. Xu, M. Sun, X. Zhang, R. Nguyen, H. Lei, J. F. Shern, C. J. Thiele, Z. Liu

This study identifies a cooperative interaction between HAND2 and MYCN in neuroblastoma that regulates enhancer binding and gene transcription, and shows that targeting these factors suppresses tumor growth.

bioRxiv · May 18, 2022 · PreprintCancer Biology

MEK1/2 in Rhabdomyosarcoma

K. A. Crawford, M. M. Cleary, C. A. Ricker, M. N. Svalina, J. F. Shern, H.-I. H. Chen, N. E. Berlow, C. A. Keller, G. A. Li

This study evaluates the combination of MEK inhibitor cobimetinib and chemotherapy in rhabdomyosarcoma, finding no significant additive or synergistic effects and potential antagonistic effects on chemotherapy efficacy.

bioRxiv · May 28, 2019 · PreprintCancer Biology